Last reviewed · How we verify
Skin and Skin Structure Citrobacter Infection
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Ciprofloxacine · Poitiers University Hospital
- Gentamicin · Merck & Co.
- Azactam · Bristol-Myers Squibb
Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent. - Noroxin
- Floxin
- Cipro · Bayer AG
- Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Skin and Skin Structure Citrobacter Infection patent landscape — cliff calendar, originator estates, attackable patents
- Skin and Skin Structure Citrobacter Infection treatment landscape brief
- Skin and Skin Structure Citrobacter Infection treatment updates RSS
Frequently asked questions about Skin and Skin Structure Citrobacter Infection
What drugs treat Skin and Skin Structure Citrobacter Infection?
Tracked treatments include Ramycin, Garamycin, Ciprofloxacine, Gentamicin, Azactam, Noroxin, Floxin, Cipro.
What is the treatment for Skin and Skin Structure Citrobacter Infection?
Standard treatment for Skin and Skin Structure Citrobacter Infection includes Ramycin, Garamycin, Ciprofloxacine, Gentamicin, Azactam. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Skin and Skin Structure Citrobacter Infection patent cliff · Skin and Skin Structure Citrobacter Infection CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Ciprofloxacine · Poitiers University Hospital
- Treatment: Gentamicin · Merck & Co.
- Treatment: Azactam · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing